Ethical challenges posed by zidovudine treatment to reduce vertical transmission of HIV. 1994

R Bayer

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D004992 Ethics, Medical The principles of professional conduct concerning the rights and duties of the physician, relations with patients and fellow practitioners, as well as actions of the physician in patient care and interpersonal relations with patient families. Medical Ethics
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015997 Neonatal Screening The identification of selected parameters in newborn infants by various tests, examinations, or other procedures. Screening may be performed by clinical or laboratory measures. A screening test is designed to sort out healthy neonates (INFANT, NEWBORN) from those not well, but the screening test is not intended as a diagnostic device, rather instead as epidemiologic. Infant, Newborn, Screening,Newborn Infant Screening,Newborn Screening,Neonatal Screenings,Newborn Infant Screenings,Newborn Screenings,Screening, Neonatal,Screening, Newborn,Screening, Newborn Infant,Screenings, Neonatal,Screenings, Newborn,Screenings, Newborn Infant
D018445 Infectious Disease Transmission, Vertical The transmission of infectious disease or pathogens from one generation to another. It includes transmission in utero or intrapartum by exposure to blood and secretions, and postpartum exposure via breastfeeding. Fetomaternal Infection Transmission,Infection Transmission, Fetomaternal,Infection Transmission, Maternal-Fetal,Infection Transmission, Vertical,Maternal-Fetal Infection Transmission,Mother-to-Child Transmission,Pathogen Transmission, Vertical,Vertical Infection Transmission,Vertical Infectious Disease Transmission,Vertical Transmission of Infectious Disease,Infection Transmission, Maternal Fetal,Maternal Fetal Infection Transmission,Mother to Child Transmission,Mother-to-Child Transmissions,Transmission, Fetomaternal Infection,Transmission, Maternal-Fetal Infection,Transmission, Mother-to-Child,Transmission, Vertical Infection,Transmission, Vertical Pathogen,Transmissions, Mother-to-Child,Vertical Pathogen Transmission

Related Publications

R Bayer
March 1995, The New England journal of medicine,
R Bayer
March 1995, The New England journal of medicine,
R Bayer
March 1995, The New England journal of medicine,
R Bayer
December 2000, Journal of acquired immune deficiency syndromes (1999),
R Bayer
July 1994, Communicable disease report. CDR weekly,
R Bayer
May 1981, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
R Bayer
May 1981, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
R Bayer
October 2020, Respirology (Carlton, Vic.),
R Bayer
January 2020, Innovations in clinical neuroscience,
Copied contents to your clipboard!